Australian molecular Dx firm targets $9.6M in financing

08/2/2013 | GenomeWeb Daily News (free registration)

Genetic Technologies is looking to obtain about $9.6 million through an offering of its company stock. The Australian molecular diagnostics company will use part of the proceeds from the offering to extend the U.S. reach of its BrevaGen test, which is used to diagnose breast cancer.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX